Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Understanding the signals that delay the spread of follicular lymphoma could provide new therapeutic targets

Scientists at the National Cancer Institute (NCI), have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis.

18 Nov 2004

Some allergic conditions could increase your risk of suffering from blood cancer

Some allergic conditions could increase your risk of suffering from blood cancer as an adult, according to a new study published in the November 2004 issue of BMC Public Health. This is important news for the increasingly large numbers of allergy sufferers worldwide.

4 Nov 2004

People with diabetes mellitus have three to four times the risk of developing liver cancer

People with diabetes mellitus have three to four times the risk of developing liver cancer, and more than twice the risk of developing pancreatic cancer than non-diabetic individuals, according to research presented at the Third Annual Frontiers in Cancer Prevention Research Meeting in Seattle.

18 Oct 2004

Hepatitis C infection increases likelihood of developing non-Hodgkin's lymphoma significantly

Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented at the Third Annual Frontiers in Cancer Prevention Research meeting.

18 Oct 2004

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Approximately half of patients with aggressive non-Hodgkin's lymphoma (NHL) fail to receive the recommended dose and schedule of chemotherapy, reducing their chances for remission or cure.

20 Sep 2004

Health problems among timber workers exposed to industry chemical PCP are to be investigated

The project, funded by the Ministry of Health, aims to ascertain whether timber workers exposed to the PCPs (pentachlorophenols) are dying earlier, getting cancers more often and suffering more chronic health problems, including fatigue, nausea and neuropsychological dysfunction.

13 Sep 2004

Exposure to simian virus 40 (SV40) is not associated with cancer in humans

Two upcoming studies by scientists at the National Cancer Institute (NCI), provide further evidence that exposure to simian virus 40 (SV40) is not associated with cancer in humans.

23 Aug 2004

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Omega-3's - fatty acids, can be produced in bioengineered plants

Long-chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) have benefits regarding cardiovascular and inflammatory function, certain types of cancer, and maternal and infant health, according to recent peer-reviewed studies.

2 Jul 2004

Results from study of Rituxan in rheumatoid arthritis show promise

Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.

16 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Cancer rates falling in the US

The nation's leading cancer organizations report that Americans' risk of getting and dying from cancer continues to decline and survival rates for many cancers continue to improve.

3 Jun 2004

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Umbilical cord blood and bone marrow transplants at Loyola University Health System, Maywood, Ill., are curing or slowing the progression of many cancers originating in the bone marrow (i.e., leukemia, myeloma) or lymphatic system (lymphoma).

3 Jun 2004

Non Hodgkin's Lymphoma News and Research

Further Reading

Association noted between certain non-lver cancers and hepatitis C

FDA knocks back anticancer drug Marqibo

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Bcl-6 oncogene - genetic target for lymphoma treatment

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Single dose phase I data on CG53135 for the prevention of oral mucositis

Understanding the signals that delay the spread of follicular lymphoma could provide new therapeutic targets

Some allergic conditions could increase your risk of suffering from blood cancer

People with diabetes mellitus have three to four times the risk of developing liver cancer

Hepatitis C infection increases likelihood of developing non-Hodgkin's lymphoma significantly

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Health problems among timber workers exposed to industry chemical PCP are to be investigated

Exposure to simian virus 40 (SV40) is not associated with cancer in humans

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Omega-3's - fatty acids, can be produced in bioengineered plants

Results from study of Rituxan in rheumatoid arthritis show promise

Drug Tarceva improves survival chance for patients with advanced lung cancer

Cancer rates falling in the US

Umbilical cord blood and bone marrow transplants slow the progression of many cancers

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News